These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9698663)

  • 1. Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group.
    Mikkola AK; Ruutu ML; Aro JL; Rannikko SA; Salo JO
    Br J Urol; 1998 Jul; 82(1):63-8. PubMed ID: 9698663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group.
    Aro JL; Haapiainen RK; Rannikko SA; Alfthan OS
    Br J Urol; 1989 May; 63(5):512-4. PubMed ID: 2659136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
    Hedlund PO; Ala-Opas M; Brekkan E; Damber JE; Damber L; Hagerman I; Haukaas S; Henriksson P; Iversen P; Pousette A; Rasmussen F; Salo J; Vaage S; Varenhorst E;
    Scand J Urol Nephrol; 2002; 36(6):405-13. PubMed ID: 12623503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study.
    Hedlund PO; Henriksson P
    Urology; 2000 Mar; 55(3):328-33. PubMed ID: 10699602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate.
    Mikkola A; Aro J; Rannikko S; Oksanen H; Ruutu M;
    Scand J Urol Nephrol; 2005; 39(4):294-300. PubMed ID: 16261661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy.
    Mikkola A; Aro J; Rannikko S; Ruutu M;
    Prostate; 2007 Mar; 67(4):447-55. PubMed ID: 17219379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high pretreatment plasma oestradiol level is associated with a low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer.
    Mikkola AK; Aro JL; Rannikko AS; Ruutu ML;
    BJU Int; 2008 May; 101(9):1090-5. PubMed ID: 18070186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial.
    Hedlund PO; Johansson R; Damber JE; Hagerman I; Henriksson P; Iversen P; Klarskov P; Mogensen P; Rasmussen F; Varenhorst E;
    Scand J Urol Nephrol; 2011 Nov; 45(5):346-53. PubMed ID: 21627403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. Finnprostate Group.
    Haapiainen R; Rannikko S; Alfthan O
    Br J Urol; 1990 Jul; 66(1):94-7. PubMed ID: 2132303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group.
    Aro J; Ruutu M; Juusela H; Hansson E; Permi J
    Ann Chir Gynaecol Suppl; 1993; 206():5-8. PubMed ID: 8291869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orchiectomy versus oestrogen in the treatment of advanced prostatic cancer.
    Haapiainen R; Rannikko S; Ruutu M; Ala-Opas M; Hansson E; Juusela H; Permi J; Saarialho M; Viitanen J; Alfthan O
    Br J Urol; 1991 Feb; 67(2):184-7. PubMed ID: 2004233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deleterious effects of low-dose oestrogen therapy on coronary status in patients with prostatic cancer.
    Henriksson P; Linde B; Edhag O
    Eur Heart J; 1987 Jul; 8(7):779-84. PubMed ID: 3653128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study.
    Haapiainen R; Rannikko S; Alfthan O
    Br J Urol; 1986 Oct; 58(5):528-33. PubMed ID: 3779355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular follow-up of patients with prostatic cancer treated with single-drug polyestradiol phosphate.
    Henriksson P; Eriksson A; Stege R; Collste L; Pousette A; von Schoultz B; Carlström K
    Prostate; 1988; 13(3):257-61. PubMed ID: 3211807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of cardiovascular complications in patients with prostatic cancer treated with estrogen.
    Henriksson P; Johansson SE
    Am J Epidemiol; 1987 Jun; 125(6):970-8. PubMed ID: 3578255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population.
    Aro J
    Prostate; 1991; 18(2):131-7. PubMed ID: 2006119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time for revival of estrogens in the treatment of advanced prostatic carcinoma? Pharmacokinetics, and endocrine and clinical effects, of a parenteral estrogen regimen.
    Henriksson P; Carlström K; Pousette A; Gunnarsson PO; Johansson CJ; Eriksson B; Altersgård-Brorsson AK; Nordle O; Stege R
    Prostate; 1999 Jul; 40(2):76-82. PubMed ID: 10386467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orchiectomy, estrogen therapy and radiotherapy in locally advanced (T3-4 M0) prostatic cancer.
    Aro J; Haapiainen R; Kajanti M; Rannikko S; Alfthan O
    Scand J Urol Nephrol Suppl; 1988; 110():103-7. PubMed ID: 3187397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma.
    Carlström K; Stege R; Henriksson P; Grande M; Gunnarsson PO; Pousette A
    Prostate; 1997 May; 31(3):193-7. PubMed ID: 9167772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.
    Hedlund PO; Damber JE; Hagerman I; Haukaas S; Henriksson P; Iversen P; Johansson R; Klarskov P; Lundbeck F; Rasmussen F; Varenhorst E; Viitanen J;
    Scand J Urol Nephrol; 2008; 42(3):220-9. PubMed ID: 18432528
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.